Physician profile

Oliver T Phan

Nephrology (Internal Medicine) · Edina, MN

NPI 1942463229

$609.29

in general payments reported to CMS, 2019-2025

16 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$28.50

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Otsuka America Pharmaceutical, INC. $181.94 2019-2020
Travere Therapeutics, INC. $71.90 2019-2024
Astrazeneca Pharmaceuticals LP $56.14 2019-2020
Opko Pharmaceuticals, LLC $35.20 2019-2020
Astellas Pharma US INC $34.26 2019-2020
Mayne Pharma Commercial LLC $32.10 2019
Genzyme Corporation $25.90 2019
Tetraphase Pharmaceuticals, INC. $25.00 2020
Octapharma USA, INC. $21.51 2019
Alexion Pharmaceuticals, INC. $20.76 2019
Akebia Therapeutics INC $20.50 2019
Paratek Pharmaceuticals, INC. $18.36 2020
Lundbeck LLC $18.31 2019
Amgen INC. $17.79 2020
Mallinckrodt Enterprises LLC $14.84 2019
Show all 16 companies
CompanyGeneral paymentsYearsTop products
Shire North American Group INC $14.78 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Oliver T Phan

$609.29

in general payments reported 2019-2025

Years
2019-2024
Top company
Otsuka America Pharmaceutical, INC.

https://glasscript.com/doctor/845486/oliver-t-phan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.